Movatterモバイル変換


[0]ホーム

URL:


SG11202101455TA - Methods and compositions for adoptive t cell therapy incorporating induced notch signaling - Google Patents

Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Info

Publication number
SG11202101455TA
SG11202101455TASG11202101455TASG11202101455TASG11202101455TASG 11202101455T ASG11202101455T ASG 11202101455TASG 11202101455T ASG11202101455T ASG 11202101455TASG 11202101455T ASG11202101455T ASG 11202101455TASG 11202101455T ASG11202101455T ASG 11202101455TA
Authority
SG
Singapore
Prior art keywords
adoptive
compositions
methods
cell therapy
notch signaling
Prior art date
Application number
SG11202101455TA
Inventor
Stanley Riddell
Irwin Bernstein
Margot Pont
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer ResfiledCriticalHutchinson Fred Cancer Res
Publication of SG11202101455TApublicationCriticalpatent/SG11202101455TA/en

Links

Classifications

Landscapes

SG11202101455TA2018-08-282019-08-28Methods and compositions for adoptive t cell therapy incorporating induced notch signalingSG11202101455TA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201862723936P2018-08-282018-08-28
PCT/US2019/048574WO2020047099A1 (en)2018-08-282019-08-28Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Publications (1)

Publication NumberPublication Date
SG11202101455TAtrue SG11202101455TA (en)2021-03-30

Family

ID=67982131

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11202101455TASG11202101455TA (en)2018-08-282019-08-28Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Country Status (9)

CountryLink
US (1)US20210292711A1 (en)
EP (1)EP3844266A1 (en)
JP (1)JP2021534785A (en)
CN (1)CN112930393A (en)
AU (1)AU2019329984A1 (en)
BR (1)BR112021003830A2 (en)
CA (1)CA3110089A1 (en)
SG (1)SG11202101455TA (en)
WO (1)WO2020047099A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20220241335A1 (en)*2019-07-112022-08-04H. Lee Moffitt Cancer Center And Research Inst5Itute, Inc.Engineering notch ligands to enhance the anti-tumor activity of adoptively transferred t cells
BR112022021551A2 (en)2020-04-282023-01-03Lyell Immunopharma Inc METHODS TO CULTIVATE CELLS
WO2022165367A1 (en)*2021-01-292022-08-04Fred Hutchinson Cancer Research CenterMethods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
CN113832102B (en)*2021-09-272024-03-12苏州东岭生物技术有限公司CD3/CD28/DLL4 magnetic beads, and preparation method and application thereof
CN116716349B (en)*2023-08-012023-10-31江苏集萃药康生物科技股份有限公司Construction method and application of DLL4 humanized mouse model

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA136551A (en)1911-08-031911-10-31Hedwig HeeronRolling mill
US4690915A (en)1985-08-081987-09-01The United States Of America As Represented By The Department Of Health And Human ServicesAdoptive immunotherapy as a treatment modality in humans
IE20030749A1 (en)1991-05-032003-11-12Indiana University FoundationHuman notch and delta binding domains in torporythmic proteins, and methods based thereon
US5420032A (en)1991-12-231995-05-30Universitge LavalHoming endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en)1992-05-051998-08-11Institut PasteurNucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5780300A (en)1995-09-291998-07-14Yale UniversityManipulation of non-terminally differentiated cells using the notch pathway
WO1997034634A1 (en)1996-03-201997-09-25Sloan-Kettering Institute For Cancer ResearchSingle chain fv constructs of anti-ganglioside gd2 antibodies
DE69733695T2 (en)*1996-11-072006-05-18Lorantis Ltd. NOTCH LIGANDS FOR USE IN IMMUNOTHERAPY
CA2343156A1 (en)1998-09-042000-03-16Sloan-Kettering Institute For Cancer ResearchFusion receptors specific for prostate-specific membrane antigen and uses thereof
CA2410510A1 (en)2000-06-022001-12-13Memorial Sloan-Kettering Cancer CenterArtificial antigen presenting cells and methods of use thereof
US6984522B2 (en)2000-08-032006-01-10Regents Of The University Of MichiganIsolation and use of solid tumor stem cells
US6689744B2 (en)2000-09-222004-02-10Genentech, Inc.Notch receptor agonists and uses
US20030119771A1 (en)2001-08-222003-06-26Rompaey Luc VanModulators of bone homeostasis identified in a high-throughput screen
JP2003093048A (en)*2001-09-262003-04-02Asahi Kasei Corp Culture medium for manufacturing new cell preparations
US20030170238A1 (en)2002-03-072003-09-11Gruenberg Micheal L.Re-activated T-cells for adoptive immunotherapy
JP2005520519A (en)2002-03-152005-07-14セレクティス Hybrid and single chain meganucleases and uses thereof
WO2003087159A2 (en)*2002-04-052003-10-23Lorantis LimitedModulators of the notch signalling pathway and uses thereof in medical treatment
US7446190B2 (en)2002-05-282008-11-04Sloan-Kettering Institute For Cancer ResearchNucleic acids encoding chimeric T cell receptors
EP1549347A1 (en)*2002-10-092005-07-06Lorantis LimitedModulation of immune function
JP2006517533A (en)*2003-01-232006-07-27ロランティス リミテッド Treatment of autoimmune diseases using activators of the Notch signaling pathway
CA2514517A1 (en)2003-01-282004-08-12CellectisUse of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
CA2589279A1 (en)*2004-11-242006-06-01Val-Chum, S.E.C.Methods to identify, prepare, and use naive t cell recent thymic emigrants
WO2007027226A2 (en)*2005-04-282007-03-08Board Of Regents, The University Of Texas SystemSystems and methods for the production of differentiated cells
ES2384440T3 (en)2005-10-182012-07-04Precision Biosciences Rationally designed meganucleases with sequence specificity and altered DNA binding affinity
UA102061C2 (en)2006-10-192013-06-10Дженентек, Інк.Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
US7915390B2 (en)2006-10-192011-03-29Genentech, Inc.Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
EP2115128A2 (en)*2007-01-302009-11-11Deutsches Rheuma-Forschungszentrum BerlinMethod for modulating the immune response by activating or inactivating the notch and/or stat4 signal path
CA2682527C (en)2007-03-302017-07-11Memorial Sloan-Kettering Cancer CenterConstitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2010054010A1 (en)2008-11-072010-05-14Fabrus LlcAnti-dll4 antibodies and uses thereof
US20110286916A1 (en)2008-11-202011-11-24Jose Miguel Aste-AmezagaGeneration and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2010141249A2 (en)2009-06-022010-12-09Merck Sharp & Dohme Corp.Generation, characterization and uses thereof of anti-notch3 antibodies
EP2571512B1 (en)2010-05-172017-08-23Sangamo BioSciences, Inc.Novel dna-binding proteins and uses thereof
PH12013501201A1 (en)2010-12-092013-07-29Univ PennsylvaniaUse of chimeric antigen receptor-modified t cells to treat cancer
WO2013126726A1 (en)2012-02-222013-08-29The Trustees Of The University Of PennsylvaniaDouble transgenic t cells comprising a car and a tcr and their methods of use
FI3597749T3 (en)2012-05-252023-10-09Univ California METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION
WO2014039044A1 (en)*2012-09-062014-03-13The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMethods of producing t memory stem cell populations
US8697359B1 (en)2012-12-122014-04-15The Broad Institute, Inc.CRISPR-Cas systems and methods for altering expression of gene products
EP3705490B1 (en)2012-12-122024-03-06The Broad Institute, Inc.Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US10696946B2 (en)*2013-02-222020-06-30The Board Of Trustees Of The University Of IllinoisT-REG cell expansion
US9683039B2 (en)2013-03-142017-06-20New York UniversityNotch agonists for the treatment of cancer
WO2015071474A2 (en)2013-11-182015-05-21Crispr Therapeutics AgCrispr-cas system materials and methods
KR20170007449A (en)2014-05-222017-01-18프레드 헛친슨 켄서 리서치 센터Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
BR112016028537A2 (en)2014-06-042017-08-22Hutchinson Fred Cancer Res stem cell expansion and graft using notch 1 and / or notch 2 agonists
AU2015339402B2 (en)*2014-10-272021-08-26Fred Hutchinson Cancer CenterCompositions and methods for boosting the efficacy of adoptive cellular immunotherapy
JP6976939B2 (en)*2015-10-202021-12-08フジフィルム セルラー ダイナミクス,インコーポレイテッド Creation of multilineage hematopoietic progenitor cells by genetic programming
MA45488A (en)*2015-10-222018-08-29Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
US11154573B2 (en)*2015-10-302021-10-26The Regents Of The University Of CaliforniaMethods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
CN109312307A (en)*2016-04-082019-02-05多伦多大学管理委员会 Methods for generating progenitor T cells from stem cells and/or progenitor cells and uses thereof
WO2018017827A1 (en)2016-07-222018-01-25Fred Hutchinson Cancer Research CenterBi-specific molecule for cell-specific notch inhibition and related methods and compositions

Also Published As

Publication numberPublication date
AU2019329984A1 (en)2021-03-11
CA3110089A1 (en)2020-03-05
US20210292711A1 (en)2021-09-23
JP2021534785A (en)2021-12-16
CN112930393A (en)2021-06-08
BR112021003830A2 (en)2021-07-20
WO2020047099A1 (en)2020-03-05
EP3844266A1 (en)2021-07-07

Similar Documents

PublicationPublication DateTitle
IL275263A (en)Compositions and methods for inhibiting t cell exhaustion
SG11202008659TA (en)Cartyrin compositions and methods for use
SG11202101455TA (en)Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
SG11202104017VA (en)Tyk2 inhibitors and uses thereof
IL280134A (en)Anti-cd112r compositions and methods
ZA201903327B (en)Compositions and methods for the induction of cd8+ t¿cells
IL282447A (en)Methods and compositions for ocular cell therapy
SG11202105502RA (en)Methods for treatment using adoptive cell therapy
IL283409A (en)Tyk2 inhibitors and uses thereof
IL275075A (en)Phenotypic markers for cell therapy and related methods
TW201613966A (en)SynTac polypeptides and uses thereof
SG10202104804PA (en)Methods and compositions for dosing in adoptive cell therapy
SG11202101996QA (en)Improved therapeutic t cell
EP3645708A4 (en)Compositions and methods for adoptive cell therapy for cancer
IL271022A (en)Compositions and methods for providing cell replacement therapy
IL273452A (en)Cell compositions comprising antigen-specific t cells for adoptive therapy
IL271256A (en)Compositions and methods for treating tauopathies
SG11202104448WA (en)Compositions and methods
IL255816B (en)Synergistic combination of neuronal viability factors and uses thereof
IL259486A (en)Agents for the treatment of diseases associated with undesired cell proliferation
ZA201902781B (en)Compositions and methods for the treatment of xerostomia
IL263218A (en)Composition and methods for microbiota therapy
GB201817444D0 (en)Methods and compositions
SG11202102538RA (en)Compositions and methods for transfecting cells
GB201819987D0 (en)Methods and compositions

[8]ページ先頭

©2009-2025 Movatter.jp